Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.…
Bausch + Lomb stock slips as eye pain drug misses endpoint
Bausch + Lomb (NYSE: BLCO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 13,000 employees.
The shares were at 19.38 USD on 20 November 2026, up 32.6% over 52 weeks. Its 52-week range is 14.44 USD to 21.40 USD: the price is 9.4% below the high and 34.2% above the low.
Its market capitalisation is 6.93B USD.
Bausch + Lomb reports return on equity of -5.6%, an operating margin of 9.4% and revenue up 7.3% year over year.
Its debt exceeds its cash by 4.58B USD, a debt-to-equity ratio of 0.79. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 21.93 USD is 13.2% above the current price. The next earnings report is expected on 17 February 2027.